[Pharmacological update in attention deficit hyperactivity disorder: models of intervention and new drugs]
Fernando Mulas1, Rubén Gandía, Patricia Roca
1Instituto Valenciano de Neurologia Pediatrica (INVANEP), Valencia, Spain. fernando.mulas@invanep.com
Insights
Attention deficit hyperactivity disorder (ADHD) treatment requires personalized pharmacological options based on individual patient characteristics and neuropsychological evaluations. Early intervention and psychoeducation are crucial for improving outcomes in children and adults with ADHD.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Context:
- Attention deficit hyperactivity disorder (ADHD) is a prevalent childhood neurodevelopmental disorder with lasting adult implications.
- Effective therapeutic interventions are essential for improving ADHD prognosis.
- Current research explores personalized pharmacological strategies for ADHD management.
Purpose:
- To identify optimal pharmacological treatments for ADHD tailored to individual patient profiles.
- To review emerging pharmacological agents for ADHD.
- To analyze how brain structure, biochemistry, genetics, and neurophysiology influence therapeutic choices.
Summary:
- Therapeutic interventions for ADHD are influenced by neurobiological factors, including brain anatomy, biochemistry, genetics, and neurophysiology.
- Neuropsychological studies, focusing on executive functions like attention, impulse control, and cognitive flexibility, are critical for treatment selection.
- Considering signal-to-noise characteristics aids in choosing appropriate ADHD medications.
Impact:
- Advancements in pharmacological options for ADHD offer greater specificity and applicability in clinical practice.
- Personalized treatment approaches, informed by comprehensive patient evaluation, are recommended.
- Integrating psychoeducation alongside tailored pharmacological interventions can lead to more favorable ADHD outcomes.
Abstract:
INTRODUCTION. Attention deficit hyperactivity disorder (ADHD) is the most frequent neurodevelopmental problem in childhood, with significant repercussions that continue into adulthood. This means that an appropriate therapeutic intervention is vital to improve its prognosis. AIMS. To identify the ideal pharmacological options according to the characteristics of the patient and to report on the new drugs. DEVELOPMENT. The work analyses how therapeutic interventions can be conditioned by the anatomical substrate of the brain, the biochemical bases, genetics, neurophysiological examinations, neuropsychological studies and the clinical symptoms and subtypes. A significant amount of importance is granted to neuropsychological studies, especially those dealing with the executive functions, including evaluation of attention, impulse control, and interference and cognitive flexibility. Taking into consideration the signal-to-noise characteristics can be useful when it comes to choosing the drug. CONCLUSIONS. The development of the pharmacological therapeutic options in ADHD opens up expectations concerning applicability and greater specificity in daily practice to fit the characteristics of each patient. Psychoeducation must always be included and a thorough study of each particular child is recommended. This should involve analysing the neuropsychological features of his or her brain function in order to be able to reflect on the ideal pharmacological option that allows more favourable progress.
Related Concept Videos
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Antidepressant Drugs: MAOIs and Other Agents
Pharmacodynamic Models: Overview
Drugs Affecting Neurotransmitter Release or Uptake
Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model


